abgenix.comTiter · how a medicine gets made

Stage US · Upstream
Entry US-05

UpstreamUS-05

Titer, and Why It Rose

The number everyone in upstream watches, and why quadrupling it did not make biologics cheap.

Governing number · grams per litre 4 min read Stage US of six
A hand drops liquid from a pipette onto a refractometer device beside a tablet showing data graphs
Grams per litre as the headline number of upstream.Photo: 찬희 윤 / Pexels

The Number on the Whiteboard

Titer is the concentration of your target protein in the bioreactor at harvest — typically expressed in grams per litre of cell culture fluid. In the early days of industrial antibody manufacturing, around the late 1980s and early 1990s, a 0.1 g/L run was considered workable. Today, well-optimised fed-batch processes routinely hit 3–5 g/L, and some platforms report higher. That is a roughly fifty-fold improvement across three decades, achieved without a single dramatic breakthrough — just the accumulation of better cell lines, better media, better process control, and a much clearer understanding of what Chinese hamster ovary cells actually need to perform.

The cell line is the foundation. CHO cells were not chosen for their natural productivity; they were chosen because they glycosylate human proteins in a broadly compatible way, grow in suspension, and have a long regulatory history. Early production cell lines expressed antibody at low levels because the gene integration was haphazard and selection pressure was limited. Over time, the industry developed methods to amplify target gene copy number, select for high-expressing clones with greater precision, and characterise those clones thoroughly enough to trust them across a manufacturing campaign. The cell line is the asset: a well-selected, thoroughly banked clone is worth more than any single vessel it seeds.

Media development ran in parallel. Cells fed on rich, chemically defined media — rather than undefined animal-derived supplements — grow denser and live longer, and a longer viable culture means more protein secreted per litre before harvest. The fed-batch strategy, in which concentrated nutrient feeds are added throughout the run to prevent depletion without diluting the culture, became industry standard precisely because it stretches the productive phase. A run that once lasted eight days might now run fourteen, harvesting significantly more protein from the same stainless steel vessel.

A stainless steel bioreactor with sanitary clamps and instrumentation, cleanroom light
The vessel is the cheap part of the room; what surrounds it sets the schedule.Photo: generated

Process control contributed too. Tight management of pH, dissolved oxygen, temperature, and osmolality keeps cells in a physiological state where they prioritise protein secretion. The bioreactor is not a passive container; it is an environment that must be actively maintained, and small deviations compound over a two-week run.

What Higher Titer Did Not Solve

Here is the uncomfortable arithmetic. If titer doubles, the volume of cell culture fluid you need to process in order to reach your drug substance target halves. That is a genuine saving — fewer bioreactor runs, less upstream labor, lower raw material consumption. But the downstream train — the chromatography columns, the filtration membranes, the viral inactivation hold tanks, the buffers — does not simply shrink proportionally.

Protein A capture, the affinity step that pulls the antibody out of clarified harvest fluid, is priced by the gram of antibody processed, not by the litre of fluid. So halving the volume while doubling the titer leaves roughly the same resin loading and the same number of column cycles. The resin itself remains one of the most expensive consumables in the process. Downstream costs proved stickier than upstream costs, because the hard work in downstream is not handling volume — it is handling impurities: host-cell proteins, DNA, aggregates, residual leached ligand. Those impurities do not disappear because your titer is higher. In some cases a denser, more productive culture generates more of them.

There is a further wrinkle. Titer is the concentration at harvest; what actually matters commercially is the amount of purified, specification-meeting drug substance delivered to fill-finish. Every step loses something: each chromatography step, each filtration, each hold recovers less than 100%. A higher titer fed into a process with 60% overall downstream yield delivers less than the headline number promises. Optimising titer without attending to yield and quality can shift the bottleneck downstream rather than relieve it.

Lifted out · 01

The titer trajectory

  • ~0.1 g/Ltypical early CHO antibody production, late 1980s to early 1990s
  • 3–5 g/Lroutine fed-batch performance in well-optimised modern platforms
  • ~50-foldapproximate improvement across three decades, accumulated incrementally
  • Fed-batch run length extended from roughly 8 days to 14+ days as media and feeding strategies improved

None of this diminishes the achievement. Rising titer reduced the number of manufacturing sites the industry needed to build, extended the productive life of existing capacity, and lowered the cost of goods on a per-gram basis for upstream operations. It made some biologics manufacturable at commercial scale that would otherwise have been economically inviable. But titer is one variable in a long equation — the headline number on a whiteboard that summarises decades of cell biology, and obscures almost everything that happens after harvest.

Titer is the concentration of your target protein in the bioreactor at harvest — typically expressed in grams per litre of cell culture fluid.

Single-use bioprocess bags on stainless frames
Bags are qualified per lot for extractables; the plastic is part of the product’s environment.Photo: Mark Stebnicki / Pexels

Lifted out · 02

Where the logic breaks

  • Higher titer → less fluid volume to process → genuine upstream saving
  • Protein A resin cost scales with grams of antibody loaded, not litres of fluid → downstream cost largely unchanged
  • Denser cultures can increase host-cell protein and aggregate burden → more work downstream, not less
  • Overall yield (upstream titer × downstream recovery) is the number that matters commercially; titer alone flatters the result
A chart recorder inking a slow trace on a process panel
The record, not anyone’s memory of the run, is what the batch is released against.Photo: generated

Also in Upstream